Biodesix, Inc. Announces Additional Data in Phase III Lung Cancer Diagnostic Study

SYDNEY & BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced additional data from the Phase III clinical trial for its serum protein test, VeriStrat®. Results were presented at the 15th World Conference on Lung Cancer in Sydney, Australia. Principal Investigator Vanesa Gregorc, M.D., presented primary and new secondary data from PROSE (Randomized Proteomic Stratified Phase III Study of Second-Line Erlotinib versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer) — the world’s first successful, prospective biomarker-stratified study in lung cancer to test treatment and biomarker interaction. As originally reported at the 2013 Annual Meeting of the American Society of Clinical Oncology ®, PROSE met its primary endpoint, which confirms that this serum protein test is predictive of differential treatment outcomes between two types of therapies for second-line treatment of advanced non-small cell lung cancer (NSCLC): single-agent chemotherapy or the tyrosine kinase inhibitor drug, erlotinib (Tarceva®).

Help employers find you! Check out all the jobs and post your resume.